(Download) "Pharmacokinetically Enhanced Amoxicillin/Clavulanate (2,000/125 Mg) in Acute Bacterial Rhinosinusitis Caused by Streptococcus Pneumoniae, Including Penicillin-Resistant Strains (Clinical Report)" by Nose and Throat Journal Ear ~ Book PDF Kindle ePub Free

Pharmacokinetically Enhanced Amoxicillin/Clavulanate (2,000/125 Mg) in Acute Bacterial Rhinosinusitis Caused by Streptococcus Pneumoniae, Including Penicillin-Resistant Strains (Clinical Report)

eBook details

Title: Pharmacokinetically Enhanced Amoxicillin/Clavulanate (2,000/125 Mg) in Acute Bacterial Rhinosinusitis Caused by Streptococcus Pneumoniae, Including Penicillin-Resistant Strains (Clinical Report)
Author : Nose and Throat Journal Ear
Release Date : January 01, 2006
Genre: Health & Fitness,Books,Health, Mind & Body,
Pages : * pages
Size : 251 KB

Description

Abstract We evaluated the efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2,000/125 mg) twice daily for the treatment of acute bacterial rhinosinusitis (ABRS) caused by Streptococcus pneumoniae, particularly penicillin-resistant S pneumoniae (PRSP; penicillin minimum inhibitory concentrations [MICs]: [greater than or equal to] 2 [micro]g/ml. A total of 2,482 patients received study medication (safety population). Of these, 2,324 were clinically evaluable (efficacy population), and 1,156 of them had at least one pathogen isolated at screening (bacteriology population). S pneumoniae was isolated from 371 patients in the bacteriology population, including 37 with PRSP. Follow-up in the bacteriology population on days 17 through 28 revealed that amoxicillin/clavulanate therapy was successful in 345 of 371 patients with S pneumoniae infection (93.0%) and in 36 of 37 patients with PRSP infection (97.3%), including 7 of 8 patients (87.5%) whose amoxicillin/clavulanic acid MICs were 4/2 [micro]g/ml or higher. Pharmacokinetically enhanced amoxicillin/clavulanate was generally well tolerated, as only 2.2 % of patients withdrew because of adverse events. This agent represents a valuable new therapeutic option for the empiric treatment of ABRS, particularly in areas where antimicrobial-resistant pathogens (including [beta]-lactamase-positive organisms) are prevalent, and for the treatment of patients who are at increased risk of infection with PRSP.